View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorized
October 3, 2012

OGT launches Genefficiency RNA sequencing service

UK-based Oxford Gene Technology (OGT) has introduced its Genefficiency RNA sequencing (RNA-Seq) service for discoveries at the transcriptome level.

UK-based Oxford Gene Technology (OGT) has introduced its Genefficiency RNA sequencing (RNA-Seq) service for discoveries at the transcriptome level.

The RNA-Seq service aids the identification of unknown genes and isoforms, without the need for new versions of exon or custom arrays and genome annotation updates.

The data analysis provides new information regarding the changes in transcript activity and variant analysis, while additional analysis reveals information on alternative splice junctions, allele specific expression and the identification of fusion proteins.

OGT CEO Dr Mike Evans said even though RNA-Seq is a flexible technology, considerable challenges are presented in terms of the data analysis process.

"Our optimised pipeline has been specifically designed to help researchers quickly and easily overcome these obstacles, while our purpose-built interactive reporting tool delivers meaningful, accurate publication-ready results for researchers," Evans said.

The service will leverage the OGT’s optimised sequencing project design and advanced data analysis.

"The data analysis provides new information regarding the changes in transcript activity and variant analysis, while additional analysis reveals information on alternative splice junctions, allele specific expression and the identification of fusion proteins."

The results will be presented in an interactive report. with OGT’s intuitive reporting tool enabling effective examination of the data.

The results can even be examined against a number of parameters, such as differentially expressed genes, and researchers can immediately investigate distinct isoforms for specified genes, according to OGT.

The Genefficiency RNA sequencing service has an initial experimental design, which is fully customisable to meet study objectives, with OGT advising on aspects relating to the correct combination of starting material and sequencing depth.

OGT claims that thorough quality control metrics are used to confirm that reliable, parsimonious, well-mapped reads are informing downstream analysis.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena